Capricor Therapeutics, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for serious medical conditions. Founded in 2000, the company has made significant strides in the fields of regenerative medicine and cell therapy, particularly in the treatment of cardiovascular diseases and Duchenne muscular dystrophy (DMD). Capricor's flagship product, CAP-1002, is a unique allogeneic cardiosphere-derived cell therapy that aims to improve heart function in patients with advanced heart failure. The company has garnered attention for its robust clinical trial results and commitment to advancing therapeutic options in underserved patient populations. With a strong market position and a dedication to scientific excellence, Capricor Therapeutics continues to lead the way in transforming the landscape of regenerative medicine.
How does Capricor Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Capricor Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Capricor Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address climate change at this time. As there are no emissions data or reduction initiatives available, it is unclear how Capricor Therapeutics aligns with industry standards for carbon management. The absence of emissions reporting may reflect a broader trend within the biotechnology sector, where companies are increasingly being urged to disclose their environmental impact and set ambitious sustainability goals. In summary, Capricor Therapeutics has not yet provided emissions data or climate commitments, indicating an opportunity for the company to enhance its environmental strategy and align with best practices in climate accountability.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Capricor Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.